Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns
Effendi M, Stutsky M, Curran C, Owusu K, Lee A. Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns. Blood 2018, 132: 2284. DOI: 10.1182/blood-2018-99-119379.Peer-Reviewed Original ResearchLow molecular weight heparinAnti-Xa levelsAnti-Xa level monitoringRetrospective chart reviewNon-therapeutic levelsEnoxaparin doseAdult patientsChart reviewCommon indicationDose adjustmentNursing staffBody weightDrug monitoringTherapeutic monitoringAbnormal levelsStudy periodExtreme body weightRoutine laboratory monitoringRenal replacement therapyCertain patient populationsMolecular weight heparinFavorable pharmacokinetic profileRisk of toxicityClinical decision makingEnoxaparin therapy